Spots Global Cancer Trial Database for loncastuximab tesirine
Every month we try and update this database with for loncastuximab tesirine cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma | NCT05228249 | Recurrent Diffu... Recurrent Diffu... Recurrent High ... Recurrent Prima... Recurrent Trans... Refractory Diff... Refractory Diff... Refractory High... Refractory Prim... Refractory Tran... | Autologous Hema... Carmustine Cytarabine Etoposide Loncastuximab T... Melphalan | 18 Years - | Fred Hutchinson Cancer Center | |
| Trial of Loncastuximab Tesirine in High Risk Diffuse Large B-cell Lymphoma Post Transplant | NCT05222438 | Relapsed Diffus... | loncastuximab t... | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NCT03589469 | Diffuse Large B... Diffuse Large B... | Loncastuximab t... | 18 Years - | ADC Therapeutics S.A. | |
| A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL) | NCT05144009 | Diffuse Large B... | Loncastuximab T... Rituximab | 80 Years - | ADC Therapeutics S.A. | |
| Trial of Loncastuximab Tesirine in High Risk Diffuse Large B-cell Lymphoma Post Transplant | NCT05222438 | Relapsed Diffus... | loncastuximab t... | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma | NCT04998669 | Follicular Lymp... | Loncastuximab t... Rituximab | 18 Years - | University of Miami | |
| Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma | NCT03684694 | Diffuse Large B... Mantle Cell Lym... | Loncastuximab T... Ibrutinib | 18 Years - | ADC Therapeutics S.A. | |
| A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) | NCT04970901 | B-Cell Non-Hodg... Relapsed B-Cell... Refractory B-Ce... | Loncastuximab T... Polatuzumab Ved... Glofitamab Mosunetuzumab Obinutuzumab | 18 Years - | ADC Therapeutics S.A. | |
| Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma | NCT04998669 | Follicular Lymp... | Loncastuximab t... Rituximab | 18 Years - | University of Miami | |
| A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) | NCT04970901 | B-Cell Non-Hodg... Relapsed B-Cell... Refractory B-Ce... | Loncastuximab T... Polatuzumab Ved... Glofitamab Mosunetuzumab Obinutuzumab | 18 Years - | ADC Therapeutics S.A. | |
| Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL) | NCT02669264 | Acute Lymphobla... | ADCT-402 | 12 Years - | ADC Therapeutics S.A. | |
| Loncastuximab Tesirine in WM | NCT05190705 | Waldenstrom Mac... | Loncastuximab T... Dexamethasone | 18 Years - | Dana-Farber Cancer Institute | |
| Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma | NCT04699461 | Relapsed Follic... Refractory Foll... | Loncastuximab T... Idelalisib | 18 Years - | ADC Therapeutics S.A. | |
| A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) | NCT04970901 | B-Cell Non-Hodg... Relapsed B-Cell... Refractory B-Ce... | Loncastuximab T... Polatuzumab Ved... Glofitamab Mosunetuzumab Obinutuzumab | 18 Years - | ADC Therapeutics S.A. | |
| Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma | NCT05053659 | Relapsed Non Ho... Refractory Non-... | Loncastuximab t... Venetoclax | 18 Years - | Case Comprehensive Cancer Center | |
| Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma | NCT04699461 | Relapsed Follic... Refractory Foll... | Loncastuximab T... Idelalisib | 18 Years - | ADC Therapeutics S.A. | |
| Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma | NCT04998669 | Follicular Lymp... | Loncastuximab t... Rituximab | 18 Years - | University of Miami | |
| Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NCT05672251 | Recurrent Diffu... Recurrent Grade... Recurrent High ... Recurrent Prima... Recurrent Trans... Recurrent Trans... Refractory Diff... Refractory Grad... Refractory High... Refractory Prim... Refractory Tran... Refractory Tran... | Biopsy Biospecimen Col... Computed Tomogr... Loncastuximab T... Mosunetuzumab Positron Emissi... | 18 Years - | City of Hope Medical Center | |
| Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma | NCT05053659 | Relapsed Non Ho... Refractory Non-... | Loncastuximab t... Venetoclax | 18 Years - | Case Comprehensive Cancer Center | |
| Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma | NCT05228249 | Recurrent Diffu... Recurrent Diffu... Recurrent High ... Recurrent Prima... Recurrent Trans... Refractory Diff... Refractory Diff... Refractory High... Refractory Prim... Refractory Tran... | Autologous Hema... Carmustine Cytarabine Etoposide Loncastuximab T... Melphalan | 18 Years - | Fred Hutchinson Cancer Center | |
| Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NCT03589469 | Diffuse Large B... Diffuse Large B... | Loncastuximab t... | 18 Years - | ADC Therapeutics S.A. | |
| A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma | NCT05991388 | B-cell Non Hodg... | Odronextamab Loncastuximab t... Rituximab Ifosfamide Carboplatin Etoposide Etoposide Phosp... Dexamethasone CAR T-cells (TB... | - 25 Years | University of Birmingham |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
